Lantheus falls as FDA extends review of experimental cancer diagnostic

Lantheus Holdings

18/03/2026 13:40

** Shares of drugmaker Lantheus Holdings LNTH.O fall 1.1% to $80.79

** Co on Tuesday said the FDA extended its review of LNTH‑2501, an experimental radioactive diagnostic for cancer, by three months

** Co's LNTH‑2501 is designed to help doctors spot neuroendocrine tumors, a type of cancer that starts in hormone‑producing cells, in adults and children - LNTH

** FDA action pushes the decision date to June 29, 2026, co says

** Co says the delay is linked to extra time needed to review manufacturing information, not the drug’s safety or effectiveness

** LNTH‑2501 is not yet approved and is not available for sale in the U.S. - LNTH

** Shares down ~26% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))